Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages

Emerging SARS-CoV-2 sublineages continue to cause serious COVID-19 disease, but most individuals have not received any COVID-19 vaccine for >1 year. Assessment of long-term effectiveness of bivalent COVID-19 vaccines against circulating sublineages is important to inform the potential need for vacci...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Bradley K. Ackerson, Katia J. Bruxvoort, Lei Qian, Lina S. Sy, Sijia Qiu, Julia E. Tubert, Gina S. Lee, Jennifer H. Ku, Ana Florea, Yi Luo, Radha Bathala, Julie Stern, Soon K. Choi, Harpreet S. Takhar, Michael Aragones, Morgan A. Marks, Evan J. Anderson, Cindy Ke Zhou, Tianyu Sun, Carla A. Talarico, Hung Fu Tseng
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Taylor & Francis Group 2024-12-01
Sarja:	Human Vaccines & Immunotherapeutics
Aiheet:	Bivalent XBB BA.4/BA.5 BA.4 BA.5 omicron
Linkit:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2335052
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!